Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma

New research, clinical trial outcomes, etc.
Post Reply
D.ap
Senior Member
Posts: 4137
Joined: Fri Jan 18, 2013 11:19 am

Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma

Post by D.ap »

Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma


Abstract

Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma and the clinical management of patients with unresectable, metastatic disease is still challenging. ASPS expresses an array of potentially therapeutically targetable, angiogenesis-related molecules and, importantly, it has a distinctive angiogenic phenotype marked by a peculiar tumor-associated vasculature. Several studies, conducted in transgenic mouse models and in a large variety of human tumors of different histotype, clearly proved the substantial contribution of tumor-infiltrating myeloid cells, such as myeloid derived suppressor cells, monocytes and macrophages, in the formation and maintenance of abnormal blood vessels in tumors. By immunohistochemistry we thus explored the presence and the distribution of cells expressing myeloid markers in the inflammatory infiltrate of surgical treated metastatic ASPS. Indeed, we found that myeloid cells expressing CD14 and CD163 markers constitute the prominent cells in the inflammatory infiltrate of ASPS. These macrophage-like cells form a network surrounding the endothelial cells, or, interspersed in the tumor nest, they keep deep contact with tumor cells. In this commentary, we discussed our findings in relation to the recently published paper by Kummar and colleagues reporting the clinical and molecular results of a phase II clinical trial in patients with unresectable, metastatic ASPS treated with the anti-angiogenic drug cediranib, targeting the VEGFR-1,-2,-3 tyrosine kinases.

Keywords: Immune infiltrating cells, Inflammation, Myeloid cells, Soft tissue sarcoma, Anti-angiogenic therapy

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3856484/
Debbie
D.ap
Senior Member
Posts: 4137
Joined: Fri Jan 18, 2013 11:19 am

Re: Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma

Post by D.ap »

“ By immunohistochemistry we thus explored the presence and the distribution of cells expressing myeloid markers in the inflammatory infiltrate of surgical treated metastatic ASPS. Indeed, we found that myeloid cells expressing CD14 and CD163 markers constitute the prominent cells in the inflammatory infiltrate of ASPS. “
Inflammatory cell infiltration occurs when inflammatory cells such as neutrophils, eosinophils, lymphocytes, plasmacytes, macrophages and mast cells infiltrate around the blood vessels (perivascular infiltration). ... The principal infiltrating cells and the causative diseases are shown in Table.
https://www.derm-hokudai.jp/shimizu-der ... /02-04.pdf
Debbie
Post Reply

Return to “Medical Publications”